脑机接口术语标准发布：行业规范化里程碑，开启产业化加速期

Investment Rating - The report maintains an investment rating of "Leading the Market-A" for the biopharmaceutical industry, indicating an expected price increase exceeding the benchmark index by more than 10% [10]. Core Insights - The biopharmaceutical industry has shown significant market performance over the past year, with innovations in drug development, particularly in the area of cancer therapies such as PD-1 and ADCs [2]. - The release of the YY/T 1987-2025 standard for brain-computer interface (BCI) medical devices marks a critical step in the industrialization of BCI technology in China, addressing long-standing issues of concept ambiguity and standardization [3][4]. - The establishment of a unified terminology system is expected to enhance communication between research, clinical applications, and regulatory bodies, thereby improving the efficiency of technology transfer [3]. - The report highlights the ongoing policy evolution in the BCI sector, characterized by national strategic guidance, industry collaboration, and localized implementation efforts [4][6]. Summary by Sections Industry Performance - The biopharmaceutical sector has experienced notable advancements, particularly in innovative drug therapies for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [2]. Policy Developments - The introduction of the BCI terminology standard is part of a broader policy framework aimed at fostering the development of the BCI industry, which has been recognized as a strategic priority since the launch of the China Brain Project in 2016 [3][4]. Technological Innovations - Recent breakthroughs in BCI technology, such as the "NeuroWorm" developed by the Shenzhen Institute of Advanced Technology, demonstrate China's leading position in implantable BCI solutions, with applications in treating neurological disorders [6]. Investment Recommendations - The report suggests focusing on companies involved in BCI technology, including Chengyitong, Xiangyu Medical, Aipeng Medical, Weisi Medical, Mcland, and Xinwei Medical, as potential investment opportunities [7].